Anesthesiology Doctors in Boone, NC Accepting Medicare

8 Anesthesiology doctors found. Showing 1 - 8

Kyle S Fisher, MD Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 895 State Farm Rd Ste 401, Boone, NC 28607 Phone: 828-264-4691    Fax: 828-265-4288

Scott L Vandiver, MD Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 895 State Farm Rd Ste 401, Boone, NC 28607 Phone: 828-264-4691    Fax: 828-265-4288

Tiffany H Selong, D.O. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 719a Greenway Road, Suite 100, Boone, NC 28607 Phone: 828-264-4691    Fax: 828-265-4288

Michal E Douglas, MD Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 719a Greenway Road, Suite 100, Boone, NC 28607 Phone: 828-264-4691    Fax: 828-265-4288

Dr. Daniel Craig Barnette Ii, D.O Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 719a Greenway Road, Suite 100, Boone, NC 28607 Phone: 828-264-4691

Joseph Morgan, Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 719a Greenway Road, Suite 100, Boone, NC 28607 Phone: 828-264-4691

Joshua Leprell Hastings, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 895 State Farm Rd Ste 401, Boone, NC 28607 Phone: 828-264-4691    Fax: 828-265-4288

Daniel H Nguyen, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 719a Greenway Road, Suite 100, Boone, NC 28607 Phone: 828-264-4691    Fax: 828-265-4288

News Archive

New research identifies promising drug therapy target for breast cancer

The genome of a cell is under constant attack, suffering DNA damage that requires an army of repair mechanisms to keep the cell healthy and alive. Understanding the behavior of the enzymes defending these assaults helps determine how - and where - cancer gets its foothold and flourishes.

Novel SLE Responder Index as the primary endpoint in two Phase 3 clinical trials

Human Genome Sciences, Inc. today announced publication by the journal Arthritis Care & Research of an article describing the development and use of a novel evidence-based systemic lupus erythematosus (SLE) Responder Index selected as the primary endpoint of two pivotal Phase 3 clinical trials of BENLYSTA (belimumab) in serologically active patients with SLE.

Alexza receives notification letter regarding noncompliance with NASDAQ listing rule

Alexza Pharmaceuticals, Inc. announced today that on December 17, 2015, the Company received a letter from the Nasdaq Staff indicating that the Company had not regained compliance with the $35 million market capitalization requirement for continued listing on The Nasdaq Capital Market by the end of the previously granted compliance period, which expired on December 16, 2015.

QRxPharma, Actavis enter License and Option Agreement

QRxPharma Limited announced today execution of its License and Option Agreement with Actavis, Inc. which finalised the legal terms and conditions to commercialise MoxDuo IR in the US acute pain marketplace. The LOA completion follows a 20 December 2011 signing of a binding Letter of Intent secured by a US$6 million non-refundable upfront signing fee to QRxPharma.

Today's Opinions: Applying comparative effectiveness research to a range of health indicators; Australia's model health care system; What about blocked stem cell research?

Significant comparative effectiveness research (CER) efforts should be dedicated to understanding the effectiveness of investments across broad determinants of health instead of focusing primarily within the health care domain alone (David Kindig and John Mullahy, 8/25).

Read more Medical News

› Verified 7 days ago